Plus Therapeutics, Inc. (PSTV) — 10-Q Filings
All 10-Q filings from Plus Therapeutics, Inc.. Browse 5 Quarterly Report reports with AI-powered summaries and risk analysis.
10-Q Filings (5)
-
PSTV Net Loss Widens to $16.7M Amid R&D Cuts, Cash Boosted by Equity Raises
— Oct 30, 2025 Risk: high
PLUS THERAPEUTICS, INC. (PSTV) reported a net loss of $4.423 million for the three months ended September 30, 2025, an increase from a net loss of $2.874 millio -
PSTV Swings to Profit on Derivative Gains, Boosts Liquidity
— Aug 14, 2025 Risk: high
PLUS THERAPEUTICS, INC. (PSTV) reported a significant turnaround in net income for the three months ended June 30, 2025, reaching $5.151 million, a substantial -
PLUS THERAPEUTICS Posts $4M Loss, Raises Capital Amid Going Concern Doubts
— May 30, 2025 Risk: high
PLUS THERAPEUTICS, INC. reported no revenue for the three months ended March 31, 2025, consistent with its pre-commercial stage. The company posted a net loss o -
Plus Therapeutics Reports Q2 2024 Results
— Aug 14, 2024 Risk: medium
Plus Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported a net loss of $10.5 million for the three months ended June 30, -
Plus Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024
— May 15, 2024 Risk: medium
PLUS THERAPEUTICS, INC. (PSTV) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. Plus Therapeutics, Inc. filed a 10-Q report for the period ending M
Popular Companies
AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX